BRIEF-AstraZeneca says FALCON trial met its primary endpoint By: Reuters: Company News December 08, 2016 at 08:43 AM EST * AstraZeneca announces subgroup analysis from FALCON trial comparing Faslodex (fulvestrant) to Arimidex (anastrozole) Read More >> Related Stocks: Astrazeneca Plc ADR